Please select a Capability in order to start your service request.
Adds BD Totalys™ MultiProcessor and BD Totalys™ SlidePrep for Gynecological Specimen Preparation to Cytology Instrumentation PortfolioMar 7, 2016
FRANKLIN LAKES, N.J., March. 7, 2016 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for its BD Totalys™ MultiProcessor and BD Totalys™ SlidePrep instruments.
Together with the BD FocalPoint™ SlideProfiler, these innovations comprise the full BD Totalys System, which further automates slide preparation, imaging and review for use in cervical cancer screening, as well as providing ancillary testing aliquot capability. Increasing automation in the laboratory helps to reduce the potential for human error and increases lab workflow efficiency. The BD™ DataLink middleware connects the BD Totalys instruments to a Laboratory Information System, improving laboratory efficiency while providing continuous sample tracking to ensure patients get the right results.
The BD Totalys System combined with the BD SurePath™ liquid-based Pap test offers an improved automated process for cervical cancer screening laboratories versus current methods.
“We are very pleased to introduce the BD Totalys System in the United States,” said Doug White, vice president and general manager, Women’s Health & Molecular Diagnostics. “The BD Totalys System provides clinical laboratories with a highly customizable, automated liquid-based cytology solution to help improve laboratory efficiency, enhance sample tracking and maintain high quality diagnostic results.”
The BD Totalys System provides a balance of automation and flexibility to help meet the needs of medium and high throughput cervical cancer screening labs by increasing workflow efficiency, reducing technician hands-on time and repetitive motion and improving usability, user safety, overall process quality and functionality.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.